Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitors

Lignende værker

• Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
  af: Li, Heyan, et al.
  Udgivet: (2014)
• Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
  af: Iwama, Eiji, et al.
  Udgivet: (2014)
• PICT1 expression is a poor prognostic factor in non-small cell lung cancer
  af: Okamura, Kyoko, et al.
  Udgivet: (2014)
• Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR
  af: Iwama, Eiji, et al.
  Udgivet: (2015)
• Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
  af: Tanaka, Kentaro, et al.
  Udgivet: (2017)